MedTrace Logo

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers

NCT05041543 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-04-20

No results posted yet for this study

Summary

A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

NTX-101

Eye drops, topical administration

DRUG

Placebo

Placebo as eye drops

Sponsors & Collaborators

  • Pinotbio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2021-06-15
Completion
2021-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05041543 on ClinicalTrials.gov